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Since September 2012, over 90 cases of respiratory 
disease caused by a novel coronavirus, now named 
Middle East respiratory syndrome coronavirus (MERS-
CoV), have been reported in the Middle East and 
Europe. To ascertain the capabilities and testing expe-
rience of national reference laboratories across the 
World Health Organization (WHO) European Region 
to detect this virus, the European Centre for Disease 
Prevention and Control (ECDC) and the WHO Regional 
Office for Europe conducted a joint survey in November 
2012 and a follow-up survey in June 2013. In 2013, 29 
of 52 responding WHO European Region countries and 
24 of 31 countries of the European Union/European 
Economic Area (EU/EEA) had laboratory capabilities to 
detect and confirm MERS-CoV cases, compared with 22 
of 46 and 18 of 30 countries, respectively, in 2012. By 
June 2013, more than 2,300 patients had been tested 
in 23 countries in the WHO European Region with nine 
laboratory-confirmed MERS-CoV cases. These data 
indicate that the Region has developed significant 
capability to detect this emerging virus in accordance 
with WHO and ECDC guidance. However, not all coun-
tries had developed capabilities, and the needs to do 
so should be addressed. This includes enhancing col-
laborations between countries to ensure diagnostic 
capabilities for surveillance of MERS-CoV infections 
across the European Region. 
Background
In September 2012, a novel coronavirus was first 
characterised at the Erasmus Medical Center (EMC), 
Rotterdam, the Netherlands, by genome sequencing 
of a viral isolate from a patient in Saudi Arabia with 
severe pneumonia [1] and was later designated as 
Middle East respiratory syndrome coronavirus (MERS-
CoV) [2]. Coronaviruses are enveloped viruses with a 
positive-sense, single-stranded RNA genome. They 
can cause respiratory and enteric infections in humans 
and animals [3,4]. Coronaviruses known to infect 
humans include the human hCoV-229E and hCoV-NL63 
alphacoronaviruses, as well as hCoV-OC43, hCoV-HKU1 
[5], severe acute respiratory syndrome (SARS)-CoV [6] 
and now MERS-CoV betacoronaviruses [1]. As of 22 July 
2013, there have been 90 laboratory-confirmed cases 
of human infection with MERS-CoV in the Middle East, 
North Africa and Europe, including 45 deaths. Of these, 
nine confirmed cases and five deaths directly or indi-
rectly linked to the Middle East had  been reported 
by four countries in the European Region (France, 
Germany, Italy and the United Kingdom (UK)) [7,8].
As per the current testing guidance of the World Health 
Organization (WHO), screening and confirmation of 
the MERS-CoV infection is based on detection of viral 
RNA by reverse transcription-polymerase chain reac-
tion (RT-PCR) and sequencing [9]. The testing algorithm 
includes a two-step approach: (i) screening, targeting 
the region upstream of the E gene (upE RT-PCR [10],) 
and (ii) confirmation, targeting the open reading frame 
1a (ORF1a RT-PCR [11]). Alternatively, screening and 
confirmatory testing could be done by targeting other 
specific regions in the MERS-CoV genome, such as 
RdRp and/or N genes, and sequence determination of 
the amplified product [11,12]. Surveillance recommen-
dations for human MERS-CoV infections are available 
from WHO [13] and the European Centre for Disease 
Prevention and Control (ECDC) [14]; an overview of 
these and other recommendations for the investiga-
tion of MERS-CoV cases is available in Pebody et al. 
[15]. Any probable or confirmed case should be rapidly 
reported to national authorities to enable appropri-
ate public health measures. National authorities must 
notify WHO under the International Heath Regulations 
(IHR) of any probable and/or confirmed case, and EU/
EEA countries may simultaneously report via the EU/
EEA Early Warning and Response System (EWRS).
Since laboratories are often in the front-line in the 
detection of emerging pathogens, ECDC jointly with 
WHO Regional Office for Europe conducted a rapid 
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survey in November 2012 to ascertain the capabili-
ties of laboratories across the WHO European Region 
to detect MERS-CoV [16]. Results showed that 22 of 46 
countries in the WHO European Region, including 18 
of 30 EU/EEA countries, had laboratory capability to 
detect and confirm cases of MERS-CoV. The results also 
indicated the rapid development of diagnostic capabili-
ties in the responding countries. Since the time of the 
survey, the epidemiological situation of MERS-CoV has 
evolved [7,8], including a 10-fold increase of confirmed 
cases as well as new travel-related cases and trans-
mission to secondary cases in Europe and elsewhere. 
Moreover, new diagnostic assays, including molecular 
and serological assays have been developed [11,17,18].
To determine the current level of MERS-CoV diagnostic 
capabilities in the Region and assess the recent testing 
practices in relation to national and international sur-
veillance guidance, ECDC and WHO Regional Office for 
Europe initiated a follow-up survey in June 2013. The 
results of this survey are presented here.
Survey of MERS-CoV detection and 
confirmation capabilities
The survey covered the following four areas: (i) avail-
ability of laboratory tests for detection and characteri-
sation of MERS-CoV from human specimens; (ii) criteria 
used for laboratory testing and case ascertainment in 
relation to national, EU and international guidance; (iii) 
testing experience and outcome to date per country; 
and (iv) needs for laboratory support from ECDC and/
or WHO.
The survey was administered to all countries in the 
WHO European Region including 53 Member States 
and two States Parties to the IHR (Liechtenstein and 
the Holy See), including the 31 EU/EEA countries. The 
ECDC sent the survey request by email to the National 
Microbiology Focal Points of the EU/EEA countries 
and to contact points for laboratories in the European 
Network for Diagnostics of ‘Imported’ Viral Diseases 
(ENIVD). The WHO Regional Office sent the survey by 
email to EuroFlu National Focal Points from National 
Influenza Centres (NICs) in non-EU/EEA countries and 
institutions responsible for MERS-CoV testing identi-
fied during the first survey.
Figure 1
Progressive implementation of laboratory tests for detection and confirmation of Middle East respiratory syndrome 
coronavirus in the World Health Organization European Region, by country, November 2012–June 2013 (n=52)
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EU/EEA: European Union/European Economic Area; RdRP: RNA-dependent RNA polymerase; RT-PCR: reverse transcription-poymerase chain 
reaction; WHO: World Health Organization.
a  Data for November 2012 when these tests were not yet developed.
b  Other combinations of screening/confirmation tests include in-house-developed assays as well as the use of commercially available RT-PCR 
kits for human coronaviruses.
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Data were collected until 28 June 2013 and were vali-
dated by the survey respondents on 5 August 2013.
Survey results
The survey captured data from 52 of 55 countries in 
the WHO European Region including all 31 EU/EEA 
countries, giving response rates of 94% and 100%, 
respectively. The survey captured capabilities of 72 
laboratories in the Region, of which 36 laboratories 
from 34 countries were WHO-recognised NICs and 30 
laboratories from 21 countries were partners of ENIVD.
Availability of assays for MERS-CoV laboratory 
testing
Data showed that 33 of 52 countries in the WHO 
European Region and 27 of 31 EU/EEA countries had 
implemented upE RT-PCR screening tests with a posi-
tive control. This assay was available in 51 laboratories 
in the WHO European Region and 41 laboratories in the 
EU/EEA countries. The most frequently implemented 
confirmation test was RT-PCR for ORF1b, which was 
available in 24 of 52 countries in the WHO European 
Region and 20 of 31 EU/EEA countries. Confirmation 
using RT-PCR targeting ORF1a was available in 17 of 
52 and 13 of 31 countries, respectively. Application 
of RdRp and/or N gene RT-PCR followed by sequence 
determination was confirmed by six of 52 and five of 
31 countries, respectively. Five of the responding coun-
tries in the WHO European Region indicated that they 
had serological assays for MERS-CoV testing available. 
These tests included IgG and IgM immunofluorescence 
assay, Western blot against recombinant N protein, 
serum neutralisation tests [11,17], or protein microar-
ray using in-vitro expressed coronavirus spike proteins 
as antigens [18]. Figure 1 shows the progressive imple-
mentation of screening/confirmation tests between 
November 2012 and June 2013 for MERS-CoV in the 
responding countries.
Based on the information on available tests and using 
the WHO interim case definition [12], we analysed the 
different degrees of MERS-CoV diagnostic capabilities 
in the region (Figure 2). We found that 29 of 52 coun-
tries in the Region and 24 of 31 EU/EEA countries had 
the capability to screen and confirm human MERS-CoV 
cases, compared with 22 of 46 and 18 of 30 respec-
tively, reported in the November 2012 assessment [16]. 
Only screening using upE RT-PCR was available in five 
and four of the responding countries in the Region 
and EU/EEA, respectively. Seventeen countries had no 
national-level capability for MERS-CoV detection and 
confirmation; most were located in the south-eastern 
Figure 2
Laboratory capabilities for detection and confirmation of Middle East respiratory syndrome coronavirus in the World 
Health Organization European Region, by country, June 2013 (n=52)
® ECDC/SRS/EPM-GIS, Sep/2013
No response
No screening capacity
Only upE RT-PCR screening (with positive RNA control)
RT-PCR screening and confirmation assays
Andorra
HolySee
Liechtenstein
Malta
Monaco
SanMarino
4 www.eurosurveillance.org
and eastern European part of the Region. All three EU/
EEA countries without MERS-CoV screening/confirma-
tion capability reported that referral arrangements 
were in place for shipment of specimens to other labo-
ratories in the EU.
Recommendations used for testing and testing 
experience by indication and type of specimens
The recommendations for MERS-CoV testing that were 
reported as being applied at national level were the 
WHO interim surveillance recommendations [13], fol-
lowed by 36 of 52 countries in the Region and 23 of 31 
EU/EEA countries, and the ECDC surveillance recom-
mendations [14], used in 22 of 52 and 18 of 31 coun-
tries, respectively. Other testing guidance documents 
used were issued by national authorities (16 of 52 and 
10 of 31 countries, respectively) and two countries 
followed the recommendations of the United States 
Centers for Disease Control and Prevention.
Following the respective recommendations, between 
the period of September 2012 and June 2013, 23 of 52 
countries in the Region and 19 of 31 EU/EEA countries 
reported testing of human samples for MERS-CoV. The 
number of patients tested varied by country as indi-
cated in Figure 3 and Table 1. Note that the relatively 
high numbers of patients tested in Belgium and Italy 
were due to screening for MERS-CoV being included in 
routine testing as part of surveillance for severe acute 
respiratory infections (SARI). The majority of countries 
with testing experience tested between one and 10 
patients during the studied period (13 of 23 countries 
in the Region and 11 of 19 EU/EEA).
 
Nearly 80% of all samples tested were specimens 
from the upper respiratory tract (Table 1). Specimens 
from the lower respiratory tract were used in 17% of 
all samples tested. Other types of specimens reported 
included urine and serum samples.
Excluding 1,812 patients from Belgium and Italy tested 
for MERS-CoV as part of the routine surveillance 
scheme for SARI, testing of 522 patients in the 23 coun-
tries followed the indications recommended for surveil-
lance. In 367 cases, one of the main reasons reported 
for triggering testing was the symptoms exhibited by 
the patient. Recent travel to the Middle East in patients 
with pneumonia or acute respiratory distress syn-
drome (ARDS) was reported as a reason for testing in 
319 cases, and developing of respiratory symptoms fol-
lowing close contact with a confirmed or probable case 
of MERS-CoV infection in 114 cases. Other reasons for 
Figure 3
Number of patients tested for Middle East respiratory syndrome coronavirus in the World Health Organization European 
Region, by country, September 2012–June 2013 (n=52)
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Table 1
Testing experience for Middle East respiratory syndrome coronavirus in the World Health Organization European Region, 
per country, June 2013 (n=52)
Country
Total number of 
patients tested
(positive
Patients tested per criteriona Specimen typeb
Contact Travel Symptoms Other Upper respiratory
Lower 
respiratory Other
Belgium 861 (0) 0 1 861 0 861 0 0
Croatia 1 (0) 0 1 1 0 1 0 0
Czech Republic 2 (0) 0 2 1 1 2 1 0
Denmark 10 (0) 0 10 0 0 10 0 0
Finland 2 (0) 0 2 2 0 1 1 0
France 52 (2) 7 45 52 0 99 40 0
Germany 108 (2) 85 5 5 0 7 6 85
Greece 3 (0) 1 2 3 0 3 2 0
Iceland 1 (0) 0 1 1 0 1 0 0
Ireland 2 (0) 1 1 2 0 2 2 0
Israel 29 (0) 0 13 16 0 29 6 0
Italy 1,001 (3) 14 10 996 25 732 269 0
Lithuania 1 (0) 0 1 0 0 1 0 0
Luxembourg 6 (0) 0 0 6 0 6 0 0
The Netherlands 12 (0) 4 12 9 0 12 1 1
Norway 2 (0) 0 2 1 0 3 0 0
Portugal 25 (0) 0 0 25 0 25 0 0
Romania 1 (0) 0 1 1 0 1 0 0
Russian Federation 11 (0) 0 10 11 1 9 6 4
Sweden 16 (0) 0 14 0 2 13 7 16
Switzerland 6 (0) 1 6 6 0 6 1 0
Turkey 140 (0) 0 140 140 0 97 51 0
United Kingdom 42 (4) 1 40 40 0 42 28 0
Total 2,334 (11) 114 319 2,179 29 1,963 421 106
a  Criterion ‘Contact’ refers to close physical contact with a confirmed or probable MERS-CoV case; ‘Travel’ refers to travel to the Arabian 
peninsula or neighbouring countries within 10 to 14 days before onset of illness; ‘Symptoms’ refers to febrile acute respiratory illness 
with clinical, radiological, or histopathological evidence of pulmonary parenchymal disease (e.g. pneumonia or acute respiratory distress 
syndrome).
b  Multiple specimens were collected for some patients.
Table 2
Needs for laboratory support for Middle East respiratory syndrome coronavirus detection and confirmation in the World 
Health Organization European Region, by country, June 2013 (n=52)
Area of support EU/EEA (n = 31) WHO European Region (n=52)
No support needed 11 13
Provision of primers and probes 8 23
Provision of positive control material for RT-PCR 15 32
Assistance with shipment abroad for MERS-CoV testing 7 16
Other type of support 8 12
EU/EEA: European Union/European Economic Area; MERS-CoV: Middle East respiratory syndrome coronavirus; WHO: World Health 
Organization.
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testing included patients in intensive care with severe 
acute respiratory infections for which no other causa-
tive infectious agents were detected. More than 300 
patients tested for MERS Co-V had fulfilled at least two 
of the criteria for testing. Countries that performed the 
largest part of testing were Turkey, Germany, France 
and the UK.
Need for laboratory support from ECDC and/
or WHO
When asked about laboratory support needed, 75% of 
the reporting countries in the Region and 65% of those 
in the EU/EEA identified needs for laboratory diagnos-
tic support from ECDC and/or WHO (Table 2). The most 
frequently stated need was continued provision of 
positive control material for RT-PCR (63% countries in 
the Region and 48% of EU/EEA countries). Other needs 
included training of laboratory personnel, provision 
of RT-PCR reagents and consumables, assistance with 
viral culture and serological assays.
Discussion
The findings of this study show that 10 months after 
sequence information for the first reported MERS-CoV 
case was made available [1], 29 of 52 countries in the 
WHO European Region and 24 of 31 EU/EEA countries 
have developed laboratory capabilities to detect and 
confirm MERS-CoV cases. Compared with the assess-
ment of these capabilities in November 2012 [16], an 
additional seven countries in the Region and six in 
the EU/EEA had implemented MERS-CoV detection 
and confirmation capability by June 2013. While case 
confirmation was done mainly by ORF1b RT-PCR and 
whole genome sequencing in November 2012 [16], 
several additional specific assays are now in use in 
Europe’s expert microbiology laboratories (RT-PCR for 
ORF1a, RdRp and the N gene, followed by sequencing). 
Moreover, 23 laboratories in 14 countries in the Region 
are now capable of isolating and identifying MERS-
CoV by culture, compared with 16 laboratories in eight 
countries in November 2012. Interestingly, the number 
of countries using other combinations of screening/
confirmation tests as well as whole genome sequenc-
ing has decreased as international testing recommen-
dations has become available and commonly accepted 
methods for screening and confirmation have been 
implemented.
The rapid increase in diagnostic capabilities described 
here is due to dedicated efforts at national level, to 
support from WHO via its network of NICs and from 
ECDC via dedicated laboratory networks (e.g. ENIVD) 
and to other EU initiatives. The European Virology 
Archive (EVA) for example, allowed laboratories to 
receive positive control material for the upE and ORF1a 
RT-PCR assays to set up the necessary MERS-CoV diag-
nostic assays.
However, a large proportion of laboratories still need 
support for the provision of positive control mate-
rial as well as primers and probes for RT-PCR, and 
assistance with shipment abroad for MERS-CoV test-
ing. These remaining needs are of concern, especially 
for countries neighbouring MERS-CoV endemic areas. 
Therefore, WHO is currently analysing the factors ham-
pering the uptake of MERS-CoV diagnostic assays in 
this part of the Region. The aim of this analysis is to set 
up a mechanism which ensures Region-wide deploy-
ment of laboratory diagnostic assays for MERS-CoV.
ECDC is currently supporting an external quality 
assessment scheme for MERS-CoV via ENIVD, address-
ing laboratory performance and pending gaps in capa-
bilities for detection and confirmation of MERS-CoV 
in the Region. Thus, building on existing WHO and EU 
laboratory networks, the two agencies will strive to 
maintain and further enhance diagnostic capabilities 
for MERS-CoV.
Our survey collected information on the types of clini-
cal specimens used for testing. However, we did not 
collect specific information on what proportion of 
specimens were used for MERS-CoV diagnosis vs fol-
low-up of diagnosed patients or monitoring of viral 
loads. The majority of specimens used for MERS-CoV 
testing were obtained from the upper respiratory tract 
which, according to preliminary reports, may contain 
lower viral loads than specimens from the lower respir-
atory tract [19,20]. Therefore, it is advisable to increase 
awareness among healthcare providers of the benefits 
of obtaining specimens from the lower respiratory tract 
when possible, particularly in case of disease pro-
gression, and to integrate this recommendation into 
national laboratory testing algorithms.
Importantly, the improved capabilities for MERS-CoV 
case confirmation were accompanied by increased 
testing in the European Region: since September 2012, 
over 2,300 patients have been tested in 23 countries. 
Apart from two countries that extended MERS-CoV 
detection tests to SARI patients irrespective of travel or 
contact history, the vast majority of countries focused 
on travellers with pneumonia or ARDS upon recent 
return from the Middle East and patients with close 
contact with a confirmed or probable case of MERS-
CoV infection, in compliance with international guid-
ance. However, the number of patients fulfilling these 
clinical and epidemiological criteria during the study 
period was not collected and we can therefore not esti-
mate the case-finding bias per country and across the 
Region as a whole. In September 2013, WHO published 
updated recommendations for laboratory testing of 
MERS-CoV [9]. These recommendations highlight the 
need for intensified efforts to validate serological tests 
for case finding and serological studies in risk groups 
and targeted populations. At the time of our study, 
existing serological tests had been validated against 
small numbers of convalescent sera, and there is no 
consensus on the interpretations of the results. WHO, 
ECDC and their networks will investigate possibilities 
to enhance the collaboration with countries in affected 
regions which would provide a platform for validating 
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serological assays. At the time of this study, only five 
countries indicated that they had the capability to per-
form assays for MERS-CoV-specific antibody detection.
After submission of this manuscript, three countries 
in the Region reported cases of MERS-CoV in returning 
travellers or residents of countries of the Middle East: 
Greece (one case, April 2014), the Netherlands (two 
cases, May 2014) and Austria (one case, September 
2014). In total 14 laboratory-confirmed cases have 
been reported since April 2012. More information is 
available in the updated ECDC rapid risk assessment 
from August 2014 and the epidemiological update from 
October 2014 [21,22]. 
In order to provide laboratories with the opportunity to 
assess their capabilities, a first external quality assur-
ance (EQA) panel for the detection of MERS-CoV by PCR 
was organised in spring 2014 by ENIVD with support 
of ECDC and WHO. Laboratories in 33 countries the 
Region participated in this scheme. A feasibility of a 
new global EQA scheme is currently being explored by 
WHO. A training for national public health institutes on 
laboratory preparedness and rapid establishment of 
detection assays for emerging respiratory pathogens 
will be conducted in November 2014. Based on the new 
evidence on MERS-CoV infection and new information 
on diagnostic assays, WHO issued updates of surveil-
lance, case definition and laboratory recommendations 
[ 23,24,25]. The major change compared with the pre-
vious version is that a patient may be considered as a 
confirmed case if a four-fold rise in neutralising anti-
body titre can be demonstrated, regardless of any PCR 
results.
Conclusion
The decision taken at the second meeting of the 
Emergency Committee convened by the WHO Director-
General on 17 July 2013 under the IHR was that the 
current outbreak of MERS-CoV is not a Public Health 
Emergency of International Concern (PHEIC) [26]. 
Importantly however, it was noted that while the PHEIC 
conditions had not been met, WHO, ECDC and Member 
States should continue to be vigilant in their surveil-
lance for MERS-CoV. Although only fourteen confirmed 
MERS-CoV cases have been identified in the Region 
since April 2012, the substantial amount of testing 
reported here serves as a reassurance of the exist-
ing laboratory support to MERS-CoV surveillance. As 
the present study shows, there is robust capability for 
detection and confirmation of human MERS-CoV cases 
in the EU/EEA. However, one third of the countries of 
the WHO European Region, mainly in the south-east 
and eastern part of the Region, are still lacking MERS-
CoV diagnostic capabilities. Therefore, efforts continue 
to address the remaining laboratory needs in order to 
ensure MERS-CoV detection and confirmation capabil-
ity needed for active surveillance of this emerging dis-
ease in Europe. 
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